407 related articles for article (PubMed ID: 29144441)
1. G-Protein Coupled Receptors Targeted by Analgesic Venom Peptides.
Daniel JT; Clark RJ
Toxins (Basel); 2017 Nov; 9(11):. PubMed ID: 29144441
[TBL] [Abstract][Full Text] [Related]
2. Analgesic conopeptides targeting G protein-coupled receptors reduce excitability of sensory neurons.
Sadeghi M; McArthur JR; Finol-Urdaneta RK; Adams DJ
Neuropharmacology; 2017 Dec; 127():116-123. PubMed ID: 28533165
[TBL] [Abstract][Full Text] [Related]
3. Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system.
Gottesman-Katz L; Latorre R; Vanner S; Schmidt BL; Bunnett NW
Gut; 2021 May; 70(5):970-981. PubMed ID: 33272979
[TBL] [Abstract][Full Text] [Related]
4. PD-1: A New Candidate Target for Analgesic Peptide Design.
Zhao L; Ma Y; Song X; Wu Y; Jin P; Chen G
J Pain; 2023 Jul; 24(7):1142-1150. PubMed ID: 36781089
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in non-opioid analgesic peptides.
Pérez de Vega MJ; Ferrer-Montiel A; González-Muñiz R
Arch Biochem Biophys; 2018 Dec; 660():36-52. PubMed ID: 30342013
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of G-protein-coupled receptor subtypes with venom peptides.
Näreoja K; Näsman J
Acta Physiol (Oxf); 2012 Feb; 204(2):186-201. PubMed ID: 21481193
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches to pain relief using venom-derived peptides.
Hogg RC
Curr Med Chem; 2006; 13(26):3191-201. PubMed ID: 17168706
[TBL] [Abstract][Full Text] [Related]
8. Conotoxins That Could Provide Analgesia through Voltage Gated Sodium Channel Inhibition.
Munasinghe NR; Christie MJ
Toxins (Basel); 2015 Dec; 7(12):5386-407. PubMed ID: 26690478
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Treatment of Chronic Pain by Targeting GPCRs.
Che T
Biochemistry; 2021 May; 60(18):1401-1412. PubMed ID: 33186495
[TBL] [Abstract][Full Text] [Related]
10. Modulation of pain transmission by G-protein-coupled receptors.
Pan HL; Wu ZZ; Zhou HY; Chen SR; Zhang HM; Li DP
Pharmacol Ther; 2008 Jan; 117(1):141-61. PubMed ID: 17959251
[TBL] [Abstract][Full Text] [Related]
11. Mambalgins, the Venom-origin Peptides as a Potentially Novel Group of Analgesics: Mini Review.
Brzezicki MA; Zakowicz PT
CNS Neurol Disord Drug Targets; 2018; 17(2):87-97. PubMed ID: 29268691
[TBL] [Abstract][Full Text] [Related]
12. Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula.
Chow CY; Cristofori-Armstrong B; Undheim EA; King GF; Rash LD
Toxins (Basel); 2015 Jun; 7(7):2494-513. PubMed ID: 26134258
[TBL] [Abstract][Full Text] [Related]
13. Novel G protein-coupled receptors as pain targets.
Ahmad S; Dray A
Curr Opin Investig Drugs; 2004 Jan; 5(1):67-70. PubMed ID: 14983976
[TBL] [Abstract][Full Text] [Related]
14. Venom-derived peptides inhibiting Kir channels: Past, present, and future.
Doupnik CA
Neuropharmacology; 2017 Dec; 127():161-172. PubMed ID: 28716449
[TBL] [Abstract][Full Text] [Related]
15. A new tridecapeptide with an octaarginine vector has analgesic therapeutic potential and prevents morphine-induced tolerance.
Kashkin VA; Shekunova EV; Titov MI; Eliseev II; Gureev MA; Porozov YB; Makarova MN; Makarov VG
Peptides; 2018 Jan; 99():61-69. PubMed ID: 29175519
[TBL] [Abstract][Full Text] [Related]
16. Venom-based biotoxins as potential analgesics.
Gazerani P; Cairns BE
Expert Rev Neurother; 2014 Nov; 14(11):1261-74. PubMed ID: 25234848
[TBL] [Abstract][Full Text] [Related]
17. Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach.
Klint JK; Smith JJ; Vetter I; Rupasinghe DB; Er SY; Senff S; Herzig V; Mobli M; Lewis RJ; Bosmans F; King GF
Br J Pharmacol; 2015 May; 172(10):2445-58. PubMed ID: 25754331
[TBL] [Abstract][Full Text] [Related]
18. Venom peptides as pharmacological tools and therapeutics for diabetes.
Robinson SD; Safavi-Hemami H
Neuropharmacology; 2017 Dec; 127():79-86. PubMed ID: 28689026
[TBL] [Abstract][Full Text] [Related]
19. Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens.
Cardoso FC; Dekan Z; Rosengren KJ; Erickson A; Vetter I; Deuis JR; Herzig V; Alewood PF; King GF; Lewis RJ
Mol Pharmacol; 2015 Aug; 88(2):291-303. PubMed ID: 25979003
[TBL] [Abstract][Full Text] [Related]
20. Conus toxins: targets and properties.
Heading CE
IDrugs; 2004 Nov; 7(11):1011-6. PubMed ID: 15551176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
